RP
RPRX icon

Regal Partners’s Royalty Pharma RPRX Stock Holding History

Regal Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$137M Sell
2,447,879
-176,593
-7% -$9.19M 7.58% 4
2026
Q1 		$126M Sell
2,624,472
-16,236
-0.6% -$711K 6.84% 6
2025
Q4 		$102M Buy
2,640,708
+1,205,582
+84% +$46M 5.88% 6
2025
Q3 		$50.6M Buy
1,435,126
+89,930
+7% +$3.26M 3.62% 10
2025
Q2 		$48.5M Sell
1,345,196
-90,760
-6% -$3.01M 4.1% 9
2025
Q1 		$44.7M Hold
1,435,956
– – 4.58% 8
2024
Q4 		$36.6M Buy
1,435,956
+258,355
+22% +$6.85M 3.71% 9
2024
Q3 		$33.3M Hold
1,177,601
– – 2.94% 10
2024
Q2 		$31.1M Buy
1,177,601
+217,774
+23% +$6.04M 3.22% 11
2024
Q1 		$29.1M Buy
+959,827
New +$28.3M 2.93% 13

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Regal Partners's RPRX Position: Q2 2026 in Review

Regal Partners reduced its Royalty Pharma (RPRX) stake by 6.7% in Q2 2026, selling an estimated $9.19M and leaving 2,447,879 shares worth $137M. The position accounts for 7.58% of the portfolio, ranked #4.

Regal Partners first reported a position in RPRX in Q1 2024 and has held it in 10 quarters since. 642 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Regal Partners held 2,447,879 shares of Royalty Pharma worth $137M as of Q2 2026.
  • Regal Partners sold 176,593 Royalty Pharma shares in Q2 2026, an estimated $9.19M.
  • Royalty Pharma made up 7.58% of Regal Partners's portfolio in Q2 2026, its #4 holding.
  • Regal Partners first reported a position in Royalty Pharma in Q1 2024 and has held it in 10 quarters since.
  • 642 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Regal Partners's 13F filing for Q2 2026, filed 14 Aug 2026.